While those controls, as well as larger group sizes, are necessary to draw strong conclusions, our findings raise the possibility treatment of MS patients who harbor the STK11-SNP with metformin or other inducer of metabolic stress could be a novel therapeutic approach. The gene discussed is STK11; the disease is myeloid sarcoma.